Review
Version 1
Preserved in Portico This version is not peer-reviewed
Treatable Myopathies
Version 1
: Received: 31 May 2023 / Approved: 1 June 2023 / Online: 1 June 2023 (09:17:11 CEST)
How to cite: Uy, G.G.G.C.; Rosales, R.L.; Khadilkar, S. Treatable Myopathies. Preprints 2023, 2023060076. https://doi.org/10.20944/preprints202306.0076.v1 Uy, G.G.G.C.; Rosales, R.L.; Khadilkar, S. Treatable Myopathies. Preprints 2023, 2023060076. https://doi.org/10.20944/preprints202306.0076.v1
Abstract
Myopathies are characterized by a diverse clinical picture affecting the skeletal muscle which includes weakness, fatigue and pain. Acquired myopathies are given importance because treatment is readily available however, some inherited myopathies can be treated as well. These myopathies can be grouped by etiology into infectious myopathies, autoimmune myopathies, granulomatous myopathies, metabolic myopathies, skeletal muscle channelopathies and Duchenne muscular dystrophy. Infectious myopathies are caused by microbiological agents. Autoimmune myopathies result from immunologic disorders causing inflammatory changes in the muscle. Granulomatous myopathy is associated with non-caseating granulomatous inflammation. Metabolic myopathies are caused by abnormal metabolic processes in the myocytes. Drug-induced myopathies are acute or subacute onset of muscle weakness after intake of a certain medications even at therapeutic doses. Critical illness myopathy stem from sepsis syndrome with failure to wean from respirator. Rhabdomyolysis is an acute myopathy, which is an urgent complex condition that involves rapid dissolution of damaged skeletal muscle. Skeletal channel myopathies are due to dysfunctions in the ion channels of the muscle. Duchenne muscular dystrophy is a genetic condition characterized by mutations in the dystrophin gene, resulting in pathologic muscle wasting. Therapies abound in myopathies as these are targeted in Infectious, Granulomatous and Autoimmune Myositides. Included in treatable myopathies are certain metabolic myopathies, rhabdomyolysis, periodic paralysis, critical illness myopathy and drug-induced myopathies. Symptomatic therapies are applied in channelopathies of muscle and dystrophinopathies can be potentially treated nowadays. Complementary rehabilitation practices are part of the management regimen.
Keywords
myopathies; myositis; autoimmune; infectious
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
